+44 (0) 20 7549 9987 | USA callers: 00-1-718-682-4567

Contact Us Now

Visiongain report states that ” Global Inflammatory Bowel Diseases (IBD) Drugs market set to grow to $7.6bn by 2023″

18 June 2018
Pharma

Visiongain’ has launched a new pharma report Inflammatory Bowel Diseases Drugs Market Report: Aminosalicylates, Antibiotics, Corticosteroids, Immunomodulators, Biologics, Crohn’s Disease, Ulcerative Colitis

There appear to be a marked variation in the prevalence rates of IBD. Crohn's disease and ulcerative colitis are much more common in developed countries than developing ones. One of the explanations is that there may be one or more environmental factors that increase the risk of IBD, which are presumably associated with Western diets and other lifestyle factors. The incidence rate of IBD appears to have stabilised in the West. In developing countries however, the number of new cases is growing annually. This may be due to Westernisation, changes in hygiene practices or more awareness of the disease. In any case, it seems likely that incidence and prevalence of IBD will increase in many countries around the world. As a consequence, demand for IBD drugs will rise.

The lead analyst of the report commented “The inflammatory bowel diseases (IBD) drugs market will continue to be driven by rising disease incidence and more-effective non-invasive diagnosis. The IBD therapies market contains a diverse range of drugs, including biologics, which stimulate its revenue value and expand the market. Also, the incidence of IBD in emerging national markets is expected to rise as those countries become more developed.”

Leading companies featured in the report include AbbVie, Janssen, Allergan, Shire, Takeda, Johnson & Johnson, UCB, Valeant, Astellas, Celgene, Takeda.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Report 2022-2032

The Macular Degeneration (AMD) and Other Retinal Diseases Drugs market was valued at US$25.29 billion in 2021 and is projected to grow at a CAGR of 7.87% during the forecast period 2022-2032.

25 November 2022

Read

Visiongain Publishes Top 50 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market Report 2022

Pharmaceutical Contract Manufacturing Organisations (CMOs) market is projected to grow at a CAGR of 6.9% by 2032.

25 November 2022

Read

Visiongain Publishes Dermatology CROs Market Report 2022-2032

The Dermatology CROs market was valued at US$ 5,154.8 million in 2021 and is projected to grow at a CAGR of 8.7% during the forecast period 2022-2032.

23 November 2022

Read

Visiongain Publishes Direct-to-Patient Market Report 2022-2032

The Direct-to-Patient market was valued at US$38,651 million in 2021 and is projected to grow at a CAGR of 6.1% during the forecast period 2022-2032.

22 November 2022

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever